Last night Shire was named the “Pharma Company of the Year” at the 12th Annual Scrip Awards Dinner in London.
“We are pleased to be honored by our industry peers with this award," said Shire Chief Executive Officer Flemming Ornskov, M.D., M.P.H. "We welcome this important recognition of our continued growth and our deep and enduring commitment to serving patients and families across the globe that are affected by rare diseases and highly specialized conditions.”
In a statement released today, Scrip said it “was impressed by Shire’s performance since its planned merger with AbbVie was called off in October 2014.” It also mentioned Shire’s consistent growth, increased R&D spend and leadership in rare diseases following the combination with Baxalta as reasons for the recognition.
“The very nature of what we do brings us a special and intimate relationship with our patients – the like of which I’ve never experienced at any other company in my 25 year career,” said Kim Stratton, Head of International Commercial at Shire while accepting the award on behalf of Shire. “So it is to our patients and their caregivers that we’d like to dedicate this award, many of whom I have been privileged to meet and who inspire me every day.”
The winner of this special award is chosen each year by Scrip’s senior editorial team, based on a variety of key metrics, including financial performance, strategic advances, progress in emerging markets, and advances in the drug pipeline.